Orocidin – New Insights Into The Treatment Of Periodontitis
Beverly Hills, California., June 11, 2024 (GLOBE NEWSWIRE) — Nordicus Partners Corporation (OTCQB:NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, and its 95% owned subsidiary, Orocidin A/S (“Orocidin”), announced today new insights into the treatment of periodontitis.
Related news for (NORD)
- Nordicus Partners Corporation Announces Key Milestone in Development of Orocidin’s Breakthrough Treatment for Periodontitis
- Nordicus Partners To Host Investor Relations Webinar on July 10, 2024
- Nordicus Partners Corporation Appoints Peter Severin as Chairman Of The Board of Directors
- Nordicus Partners Corporation Engages FORCE Family Office